Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

324
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
324
Asthma-I: Introduction01:29

Asthma-I: Introduction

2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

2.4K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
2.4K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

222
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
222

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An early window into immune developmental trajectory of asthma.

American journal of respiratory and critical care medicine·2026
Same author

Stability and age-specific patterns of rhinovirus circulation in children observed over 3 decades.

The Journal of allergy and clinical immunology·2026
Same author

Single cell transcriptional profiling of monocytes from asthma patients show a predisposition for an inflammatory response.

Cytotherapy·2025
Same author

Child Opportunity Index and Outcomes of Children Admitted to US PICUs for Critical Asthma.

Pediatric pulmonology·2025
Same author

Phenotype-Based Management of Recurrent Preschool Wheezing and Asthma.

The journal of allergy and clinical immunology. In practice·2025
Same author

Single-cell RNA-sequencing of circulating eosinophils from asthma patients reveals an inflammatory signature.

iScience·2025
Same journal

Response to the Letter to the Editor Regarding "Comparative Evaluation of Risk Scores for Predicting Postoperative Pulmonary Complications".

Respiratory care·2026
Same journal

Respiratory Muscle Dysfunction in Stable COPD: A Multimodal Assessment of Diaphragmatic and Cough-Related Impairment.

Respiratory care·2026
Same journal

Flow Asynchronies During Pressure Support Ventilation in Children: A Bench Model Study.

Respiratory care·2026
Same journal

Inspiratory Effort Assessment Using the Occlusion Pressure-Derived Tension-Time Index.

Respiratory care·2026
Same journal

Clinical Usage of High-Flow Nasal Cannula Across Disease Categories and Care Settings: A Nationwide Cohort Study in Japan.

Respiratory care·2026
Same journal

Efficacy of Mechanical Insufflation-Exsufflation Devices as Analyzed in Lung Models: Systematic Review and Network Meta-Analysis of Peak Expiratory Flow Data.

Respiratory care·2026
See all related articles

Related Experiment Video

Updated: May 25, 2025

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

40.1K

Asthma Phenotypes and Biomarkers.

Jocelyn R Grunwell1, Anne M Fitzpatrick2

  • 1Dr. Grunwell is affiliated with Division of Critical Care Medicine, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia.

Respiratory Care
|February 27, 2025
PubMed
Summary
This summary is machine-generated.

Severe asthma heterogeneity is better understood through type 2-high and type 2-low inflammatory phenotypes. Biomarker evaluation guides biologic selection for targeted severe asthma treatment in adults and children.

Keywords:
allergic sensitizationasthmabiomarkerclusterendotypeexacerbationlatent class analysisphenotypetype-2 inflammation

More Related Videos

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.4K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

22.3K

Related Experiment Videos

Last Updated: May 25, 2025

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

40.1K
Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.4K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

22.3K

Area of Science:

  • Immunology and Pulmonology
  • Translational Medicine
  • Clinical Phenotyping

Background:

  • Asthma presents diverse phenotypes in adults and children, with severe cases exhibiting persistent symptoms despite treatment.
  • Research focuses on severe asthma heterogeneity, leading to the identification of type 2-high and type 2-low inflammatory profiles.
  • Type 2-high asthma involves specific immune pathways and eosinophilic inflammation, while type 2-low asthma is less understood and corticosteroid-resistant.

Purpose of the Study:

  • To review the pathobiology of adult and pediatric asthma phenotypes.
  • To discuss phenotype-based treatment strategies for severe asthma, including biologic therapies.
  • To explore clinical phenotyping for guiding outpatient management and identify potential high-risk pediatric phenotypes.

Main Methods:

  • Review of existing literature on asthma pathobiology, phenotypes, and treatment.
  • Analysis of classification methods including supervised and unsupervised approaches.
  • Evaluation of biomarker panels for guiding biologic selection in severe asthma.

Main Results:

  • Severe asthma is classified into type 2-high and type 2-low phenotypes based on inflammatory markers.
  • Biologics targeting type 2-high inflammation show promise in reducing exacerbations.
  • Biomarker panels (blood eosinophils, IgE, FeNO) aid in selecting appropriate biologic therapies.

Conclusions:

  • Understanding asthma phenotypes is crucial for personalized treatment strategies.
  • Biologic therapies offer targeted options for severe asthma, particularly type 2-high.
  • Further research is needed to fully characterize type 2-low asthma and identify high-risk pediatric phenotypes, including those requiring ICU admission.